Compound derived from thunder god vine could improve outcomes for pancreatic cancer patients

The results of a pre-clinical study led by researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest how a compound derived from the thunder god vine -- an herb used in China for centuries to treat joint pain, swelling and fever -- is able to kill cancer cells and potentially improve clinical outcomes for patients with pancreatic cancer.

The medicinal plant's key ingredient, triptolide, is the basis of a water-soluble prodrug called Minnelide, which appears to attack pancreatic cancer cells and the cocoon of stroma surrounding the tumor that shields it from the body's immune system. Investigators recently published the study results in the journal Oncogenesis.

The study found that the compound's mechanism of action is the ability of triptolide (Minnelide) to disrupt what are known as super-enhancers, strings of DNA needed to maintain the genetic stability of pancreatic cancer cells and the cancer-associated-fibroblasts that help make up the stroma surrounding the cancer.

The cancer cells rely on super-enhancers for their growth and survival. We found that by disrupting these super-enhancers triptolide not only attacks the cancer cells, but also the stroma, which helps accelerate cancer cell death."

Dr. Haiyong Han, Professor, TGen's Molecular Medicine Division and one of the study's senior authors

"While triptolide has been known to be a general transcriptional inhibitor and a potent antitumor agent, we are the first to report its role in modulating super-enhancers to regulate the expression of genes, especially cancer-causing genes," said Dr. Han, who also is head of the basic research unit in TGen's Pancreatic Cancer Program.

Pancreatic cancer is the third leading cause of cancer-related death in the U.S., annually killing more than 47,000 Americans.

"There is an urgent need to identify and develop treatment strategies that not only target the tumor cells, but can also modulate the stromal cells," said Dr. Daniel Von Hoff, TGen Distinguished Professor and another senior author of the study.

"Based on our findings, using modulating compounds such as triptolide to reprogram super-enhancers may provide means for effective treatment options for pancreas cancer patients," said Dr. Von Hoff, considered one of the nation's leading authorities on pancreatic cancer.

Thunder god vine (Tripterygium wilfordii), also known as léi g?ng téng, is native to China, Japan and Korea. Traditional Chinese medicine has used the vine for more than 2,000 years as a treatment for everything from fever to inflammation and autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. The chemical compound triptolide is among the more than 100 bioactive ingredients derived from the thunder god vine.

The study -- Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts -- was published Nov. 9 in Oncogenisis.

Source:
Journal reference:

Noel, P., et al. (2020) Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Oncogenesis. doi.org/10.1038/s41389-020-00285-9.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients